查看购物车
  • Traditional Chinese
  • English
  • Japanese
印度新兴感染疾病诊断市场（按流行病学、应用、技术、感染类型、疾病类型和最终用户划分）分析与预测（2025-2035 年）
市场调查报告书
商品编码
1754872

印度新兴感染疾病诊断市场（按流行病学、应用、技术、感染类型、疾病类型和最终用户划分）分析与预测（2025-2035 年）

India Emerging Infectious Disease Diagnostics Market: Focus on Epidemiology, Application, Technology, Type of Infection, Disease Type, and End User - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

印度新兴感染疾病诊断市场规模正在快速成长，这得益于新冠肺炎、疟疾、结核病和政治热等感染疾病疫情的不断增加，以及人们对抗菌素抗药性日益增长的担忧。

诊断技术的进步，尤其是分子诊断、就地检验和人工智慧，使得快速且准确地检测病原体成为可能，这对于有效的疾病控制至关重要。国家卫生使命等政府措施和对医疗基础设施的投资进一步推动了市场的成长。此外，私人公司透过诊断链的参与以及与国际公司的合作，也促进了印度各地诊断能力的扩展，特别是在服务不足的地区。由于 COVID-19 大流行而加速的健康意识增强也推动了对及时诊断的需求。因此，市场正在迅速发展，技术创新和可近性的提高进一步促进了新兴感染疾病的检测和治疗。

有几个关键因素推动着印度新兴感染疾病诊断市场的成长。诊断技术的不断进步，尤其是 PCR 和 RT-PCR 等分子诊断技术，使得病原体检测速度更快、更准确。包括 COVID-19、疟疾、结核病和政治热在内的感染疾病疫情日益流行，推动了对高效诊断解决方案的需求。此外，国家卫生使命等政府措施以及对医疗基础设施的投资，提高了诊断工具的可用性和可近性，尤其是在农村地区。由于 COVID-19 疫情的爆发，公众健康意识增强，重视疾病的早期发现，这进一步推动了市场的成长。此外，私人诊断连锁店的兴起以及与国际诊断公司的合作，正在推动先进诊断技术在印度的普及。这些因素共同推动市场继续扩张，因为诊断工具的创新和医疗保健可近性的改善将在塑造市场的未来方面发挥关键作用。

儘管印度新兴的感染疾病诊断市场蕴藏着巨大的机会，但也面临许多挑战。其中一项主要挑战是医疗保健基础设施的不平衡，尤其是在农村和偏远地区，这限制了先进诊断技术的普及。虽然城市都市区取得了快速进展，但农村地区诊断设施的匮乏对技术的广泛应用构成了重大障碍。此外，分子诊断和就地检验检验等先进诊断测试的高昂成本可能会限制其可负担性和可近性，尤其对于医疗资源匮乏的人。监管障碍和新诊断技术的核准延迟也减缓了市场成长，因为创新解决方案的引入往往会面临官僚主义的阻碍。此外，儘管诊断需求不断增长，但能够有效操作先进诊断设备的训练有素的专业人员往往短缺，这阻碍了现有技术的有效利用。这些挑战凸显了对医疗保健基础设施、可负担性策略和能力建设措施进行重点投资的必要性，以充分发挥印度诊断市场的潜力。

印度新兴的感染疾病诊断市场目前正处于快速成长和创新阶段。这一阶段的特点是，由于感染疾病（尤其是 COVID-19、疟疾、结核病和政治热）的流行，先进诊断技术的应用日益广泛。该市场还受益于政府对医疗基础设施和诊断能力的大量投资，以及私营部门为扩大诊断工具的取得而做出的参与。分子诊断、就地检验和人工智慧的技术进步使得感染疾病检测更快、更准确，进一步推动了市场成长。在对更有效率、更易获得的诊断解决方案的需求不断增长的背景下，由于诊断中心数量的增加以及与国际公司的合作，市场正在不断扩大。然而，随着市场的成熟，需要解决定价、基础设施和监管流程的挑战。

由于技术进步、公众健康意识的提升以及政府加强医疗基础设施的倡议，印度新兴感染疾病诊断市场正在快速成长。该行业在应对日益加重的感染疾病负担、实现及时检测和改善疾病管理方面发挥关键作用。该市场涵盖广泛的诊断解决方案，包括分子诊断、就地检验和快速诊断检测 (RDT)，所有这些解决方案都在改变印度的感染疾病控制方式。

印度新兴感染疾病诊断领域的主要技术进步包括：

  • 分子诊断：聚合酵素链锁反应(PCR) 和即时PCR(RT-PCR) 等分子诊断技术的采用，彻底改变了我们检测病原体的能力，使其更加准确、快速。这些技术能够在基因层面上准确识别病毒和细菌感染，对于快速诊断新冠肺炎 (COVID-19)、结核病和疟疾等疾病至关重要。
  • 即时检测 (POCT)：即时检测设备在印度日益普及，因为它们能够在患者就诊时快速诊断。这在农村和服务欠缺地区尤其重要，因为这些地区缺乏集中式实验室。快速抗原抗体检测等即时检测技术已被证明可有效检测登革热、疟疾和新冠肺炎等疾病。
  • 人工智慧 (AI)：人工智慧和机器学习正日益机会融入诊断平台，使疾病检测和结果解读更有效率。人工智慧诊断工具有助于简化数据分析，从而加快决策速度并改善患者预后。

新兴感染疾病诊断对印度的影响：

印度面临传染性和非传染性疾病的双重负担，感染疾病持续构成重大公共卫生挑战。新冠肺炎 (COVID-19)、媒介传播感染疾病（登革热、基孔肯雅热）以及通用感染疾病等新兴感染疾病的兴起，迫切需要更先进、更广泛的诊断工具。

新冠疫情显着加速了印度诊断检测的推广，并凸显了建立强大的新兴感染疾病诊断基础设施的重要性。这一转变引起了全球对提升诊断能力需求的关注，并促使公共和私营部门投资加强印度各地的诊断服务。

政府措施和支持

印度政府一直积极主动地透过国家卫生使命（NHM）、国家结核病消除计画（NTEP）、综合疾病监测计画（IDSP）等措施来满足感染疾病的诊断需求。这些倡议旨在改善疾病监测、早期发现和治疗机会，这直接影响了对诊断服务的需求。

为因应新冠肺炎疫情，政府透过扩建实验室、津贴诊断试剂套件、简化新诊断技术核准流程等方式加大诊断检测能力提升力度，显着提高了印度感染疾病应对能力，并为未来诊断基础设施发展奠定了基础。

市场区隔对印度新兴感染疾病诊断市场的影响

细分一：按应用

  • 实验室测试
  • 护理点

实验室检验主导印度新兴感染疾病诊断市场（按应用）

从应用角度来看，实验室检测领域在2024财年占据了印度新兴感染疾病诊断市场的主导地位。实验室检测在感染疾病的诊断和管理中发挥着至关重要的作用。它涉及分析患者样本，例如血液、尿液、痰液和组织，以检测是否存在传染源。微生物培养是一种常用技术，将患者样本在特定的生长培养基中培养，以分离和鑑定细菌、真菌和寄生虫，然后在显微镜下进行观察。

细分2：依技术

  • 聚合酵素链锁反应（PCR）
  • 恒温核酸增幅技术（INAAT）
  • 次世代定序仪（NGS）
  • 免疫诊断
  • 其他技术

从技术面来看，2024财年，印度新兴的感染疾病诊断市场以PCR技术为主。 PCR技术目前已广泛应用于世界各地的实验室，因为它可以进一步扩增DNA，甚至能够分析微量的核酸。随着分子生物学技术的进步，PCR技术在疾病诊断、DNA分析、精准医疗和基因表现等多个领域得到应用。

次世代定序仪(NGS) 实现了病原体基因组的全面、高通量分析，彻底改变了感染疾病的诊断。全基因组定序 (WGS) 可以对整个病原体基因组进行定序，提供有关遗传变异、抗菌素抗药性基因和毒力因子的详细资讯。 WGS 可用于病原体的识别和表征、疫情追踪以及进化模式分析。

预计将实现显着增长的其他新技术包括数位 PCR、INAAT 和 CRISPR（成簇的规律间隔的短回文重复序列）。

细分3：按感染类型

  • 细菌
  • 病毒性的
  • 真菌
  • 其他感染（例如寄生虫）

细菌和病毒主导印度新兴感染疾病诊断市场（按感染类型）

根据感染疾病类型，细菌感染疾病诊断涉及各种方法和技术，以识别临床样本中是否存在细菌病原体。常见的细菌感染疾病包括呼吸道感染疾病，如结核病和链球菌感染疾病，以及性行为感染(STI)，如披衣菌感染、淋病和梅毒。

病毒具有变异的能力，因此即使某种病毒已被根除或控制，疾病仍可能捲土重来。正因如此，分子诊断公司正致力于开发能够检测多种病毒的检测方法。常见的感染疾病包括流感病毒、生殖器疱疹病毒、新冠肺炎病毒、肝炎病毒、腮腺炎病毒、德国麻疹、胃肠炎病毒、兹卡和伊波拉出血热。

细分4：按疾病类型

  • 呼吸道感染疾病
  • 胃肠道感染疾病
  • 性行为感染感染（STI）
  • 神经系统感染疾病
  • 移植后感染疾病
  • 其他的

呼吸道感染疾病在印度新兴感染疾病诊断市场中占主导地位（按疾病类型）

大多数分子诊断公司提供多种引起呼吸道感染疾病的细菌和病毒的检测。此外，COVID-19 疫情促使人们开发了一系列使用逆转录聚合酶炼式反应 (RT-PCR) 等传统技术以及 RT-LAMP 和 CRISPR 等新技术的检测方法。目前，一些公司提供针对甲型流感、乙型流感、呼吸道融合细胞病毒(RSV) 和 SARS-CoV-2 病毒的多重检测。

细分 5：按最终用户

  • 医院和诊所
  • 诊断实验室
  • 其他的

印度新兴感染疾病诊断市场以医院/诊所和诊断实验室为主（按最终用户）

根据最终用户，医院和诊所以及诊断实验室部门在 2024 财政年度占印度新兴感染疾病诊断市场的最大份额。医院和诊所在感染疾病诊断领域发挥关键作用，是病患评估和检测的重要中心。除了提供即时结果以快速诊断和管理的就地检验(POCT) 之外，医院和诊所还依靠实验室检测进行全面分析。一些医疗机构建立了配备最先进诊断技术的内部实验室，而其他医疗机构则与外部诊断实验室合作进行专门检测。这些实验室采用各种方法，包括 PCR 和定序等分子技术、血清学检测和基于培养的方法来准确识别和表征传染源。

印度：开发新兴市场感染疾病诊断市场的最新趋势

  • 2023年2月，赛默飞世尔科技公司与Mylab宣布建立传染病检查套件合作关係。
  • 2023 年 2 月，生技新兴企业CrisprBits 在种子前资金筹措中筹集了 25 万美元，以支持基于 CRISPR 的测试开发和商业化。
  • 2023年2月，美国食品药物管理局（FDA）批准Cepheid公司（母公司：DANAHER CORPORATION）的Xpert Mpox检测紧急使用。
  • 2022 年 8 月，Bio-Rad Laboratories, Inc. 收购了 Curiosity Diagnostics，获得了 PCR ONE 的使用权，这是 Curiosity Diagnostics 正在开发的一种用于快速检测多种病原体的技术。
  • 2021年6月，Hologic公司完成对Mobidiag的收购，扩大了分子诊断能力。
  • 2023 年 1 月，CrisprBits 开发了印度首个基于 CRISPR 的 SARS-CoV Year-2 测试。
  • 2023年3月，印度新兴企业Mylab Discovery Solutions Pvt. Ltd.与美国第一家分子诊断药物製造商AstraGene LLC成立合资企业，在美国和科威特开发分子诊断药物。
  • 2022 年 11 月，Bio-Rad Laboratories, Inc. 与 NuProbe 签订了数位 PCR 应用的独家授权合约。

印度新兴感染疾病诊断市场报告如何为您的组织增加价值？

工作流程/创新策略：印度新兴感染疾病诊断市场已根据应用、技术、感染疾病类型、疾病类型、最终用户和地区等不同类别进行了广泛细分，这有助于读者清楚地了解哪个细分市场占有最大份额以及哪个细分市场在未来几年可能增长。

成长/行销策略产品发布、升级和核准是印度新兴感染疾病诊断市场的主要发展。

竞争策略：印度新兴感染疾病诊断市场是一个分散的市场，既有参与企业，也有新兴的参与企业。本研究分析并概述了印度新兴感染疾病诊断市场中的主要企业概况，包括提供各种感染疾病分子诊断测试的现有公司。

本报告研究了印度新兴的感染疾病诊断市场，并概述了市场以及流行病学、应用、技术、感染类型、疾病类型、最终用户和参与市场的公司概况等方面的趋势。

目录

执行摘要

第一章 印度新兴感染疾病诊断市场概述

  • 市场展望
  • 市场动态

2. 印度新兴感染疾病诊断市场分析（按应用），百万美元，2023-2035

  • 概述
  • 实验室测试
  • 就地检验

3. 印度新兴感染疾病诊断市场分析（按技术），百万美元，2023-2035 年

  • 概述
  • PCR
    • 即时PCR
    • 数位PCR
  • 免疫诊断
  • 恒温核酸增幅技术（INAAT）
  • 次世代定序（NGS）
  • 其他的

4. 印度新兴感染疾病诊断市场分析（依感染类型），百万美元，2023-2035 年

  • 概述
  • 细菌
  • 病毒
  • 真菌
  • 其他的

5. 印度新兴感染疾病诊断市场分析（按疾病类型），百万美元，2023-2035 年

  • 概述
  • 呼吸道感染疾病
  • 胃肠道感染疾病
  • 性行为感染感染（STI）
  • 感染疾病
  • 移植后感染疾病
  • 其他的

6. 印度新兴感染疾病诊断市场分析（按最终用户划分），百万美元，2023-2035 年

  • 概述
  • 医院和诊所
  • 诊断实验室
  • 其他的

7. 印度新兴感染疾病诊断市场竞争基准化分析与公司概况

  • 竞争基准化分析
  • 竞争格局
    • 各公司主要策略及发展
    • 关键进展
    • 企业市场占有率分析
  • 公司简介
    • Abbott Laboratories
    • Becton, Dickson and Company
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc
    • Co-Diagnostics, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd
    • Hologic, Inc
    • QIAGEN NV
    • Thermo Fisher Scientific, Inc.
    • Siemens Healthineers AG
  • 新兴企业概况
    • Trivitron Healthcare
    • Genes2Me
    • CrisprBits
    • D-NOME Pvt Ltd.

第八章调查方法

Product Code: BHP1447SB

India Emerging Infectious Disease Diagnostics Market Industry Overview

India emerging infectious disease diagnostics market is experiencing rapid growth, driven by the increasing prevalence of infectious diseases, such as COVID-19, malaria, tuberculosis, and dengue, alongside rising concerns about antimicrobial resistance. Technological advancements in diagnostics, particularly in molecular diagnostics, point-of-care testing, and artificial intelligence, are enabling faster and more accurate detection of pathogens, which is crucial for effective disease management. The government's initiatives, such as the National Health Mission and investments in healthcare infrastructure, further bolster the growth of the market. Additionally, the private sector's involvement through diagnostic chains and partnerships with international companies is contributing to the expansion of diagnostic capabilities across India, particularly in underserved regions. The heightened awareness about health, accelerated by the COVID-19 pandemic, has also increased the demand for timely diagnostics. As a result, the market is evolving rapidly, with innovations and improved accessibility driving further advancements in the detection and treatment of emerging infectious diseases.

Several key factors are driving the growth of India's emerging infectious disease diagnostics market. Ongoing advancements in diagnostic technologies, particularly in molecular diagnostics such as PCR and RT-PCR, are enabling faster and more accurate detection of pathogens. The increasing prevalence of infectious diseases, including COVID-19, malaria, tuberculosis, and dengue, has heightened the demand for efficient diagnostic solutions. Furthermore, government initiatives such as the National Health Mission and investments in healthcare infrastructure are enhancing the availability and accessibility of diagnostic tools, particularly in rural areas. The growing awareness of public health and the emphasis on early disease detection, accelerated by the COVID-19 pandemic, have further contributed to market growth. Additionally, the rise of private diagnostic chains and partnerships with international diagnostic companies are increasing the reach of advanced diagnostic technologies across India. These factors collectively position the market for continued expansion, with innovations in diagnostic tools and greater healthcare accessibility playing a pivotal role in shaping its future.

Despite the significant opportunities, several challenges persist in India emerging infectious disease diagnostics market. One of the primary challenges is the uneven healthcare infrastructure, particularly in rural and remote areas, which limits access to advanced diagnostic technologies. While urban centers have seen rapid advancements, the lack of diagnostic facilities in rural regions poses a significant barrier to widespread adoption. Additionally, high costs associated with advanced diagnostic tests, such as molecular diagnostics and point-of-care testing, can limit their affordability and accessibility, especially for underserved populations. Regulatory hurdles and delays in approvals for new diagnostic technologies also slow down the market's growth, as the introduction of innovative solutions often faces bureaucratic obstacles. Furthermore, while the demand for diagnostics is rising, there is often a lack of trained professionals to effectively operate advanced diagnostic equipment, which hampers the effective utilization of available technologies. These challenges highlight the need for targeted investment in healthcare infrastructure, affordability strategies, and capacity-building initiatives to unlock the full potential of the diagnostic market in India.

Market Lifecycle Stage of India Emerging Infectious Disease Diagnostics:

The India Emerging Infectious Disease Diagnostics market is currently in a phase of rapid growth and innovation. This phase is characterized by the increasing adoption of advanced diagnostic technologies, driven by the rising incidence of infectious diseases, particularly COVID-19, malaria, tuberculosis, and dengue. The market is also benefiting from significant government investments in healthcare infrastructure and diagnostic capabilities, as well as from private sector participation in expanding access to diagnostic tools. Technological advancements in molecular diagnostics, point-of-care testing, and artificial intelligence are enabling faster, more accurate detection of infectious diseases, further propelling market growth. As the demand for more efficient and accessible diagnostic solutions grows, the market is in the process of scaling up, with an increasing number of diagnostic centers and partnerships with international companies. However, challenges related to affordability, infrastructure gaps, and regulatory processes still need to be addressed as the market continues to mature.

Impact on India Emerging Infectious Disease Diagnostics

India Emerging Infectious Disease Diagnostics market is experiencing rapid growth, driven by increasing technological advancements, heightened public health awareness, and government initiatives aimed at strengthening healthcare infrastructure. This sector plays a critical role in addressing the growing burden of infectious diseases, enabling timely detection, and improving disease management. The market includes a broad range of diagnostic solutions, such as molecular diagnostics, point-of-care testing, and rapid diagnostic tests (RDTs), all of which are transforming the approach to combating infectious diseases in India.

Key technological advancements in India emerging infectious disease diagnostics include:

  • Molecular Diagnostics: The adoption of molecular diagnostic technologies, such as Polymerase Chain Reaction (PCR) and Real-Time PCR (RT-PCR), has revolutionized the ability to detect pathogens with higher accuracy and speed. These technologies, which allow for the precise identification of viral and bacterial infections at a genetic level, have become indispensable in the rapid diagnosis of diseases such as COVID-19, tuberculosis, and malaria.
  • Point-of-Care Testing (POCT): Point-of-care testing devices have been gaining traction in India, enabling rapid diagnosis at the site of patient care. This is especially important in rural and underserved areas where access to centralized laboratories may be limited. POCT technologies, such as rapid antigen and antibody tests, have proven to be effective in detecting diseases such as dengue, malaria, and COVID-19.
  • Artificial Intelligence (AI): AI and machine learning are increasingly being incorporated into diagnostic platforms, improving the efficiency of disease detection and interpretation of results. AI-driven diagnostic tools are helping streamline data analysis, enabling faster decision-making and better patient outcomes.

Impact of India Emerging Infectious Disease Diagnostics:

India faces a dual burden of communicable diseases and non-communicable diseases, with infectious diseases continuing to pose significant public health challenges. The rise of emerging infectious diseases, such as COVID-19, as well as vector-borne diseases (dengue, chikungunya), and zoonotic diseases, has created an urgent demand for more sophisticated and widespread diagnostic tools.

The COVID-19 pandemic significantly accelerated the adoption of diagnostic testing in India, highlighting the importance of having a robust diagnostic infrastructure for emerging diseases. This shift has brought global attention to the need for improved diagnostic capabilities, and it has encouraged investments in both public and private sectors to enhance diagnostic services across the country.

Government Initiatives and Support:

The Indian government has been proactive in addressing the diagnostic needs for infectious diseases through initiatives such as the National Health Mission (NHM), National Tuberculosis Elimination Program (NTEP), and Integrated Disease Surveillance Program (IDSP). These initiatives aim to improve disease surveillance, early detection, and treatment access, which directly influences the demand for diagnostic services.

In response to COVID-19, the government ramped up efforts to increase diagnostic testing capacity, including expanding testing sites, subsidizing diagnostic kits, and streamlining approval processes for new diagnostic technologies. These actions have significantly improved India's capacity to respond to infectious disease outbreaks and have laid the foundation for future diagnostic infrastructure development.

Market Segmentation for Impact on India Emerging Infectious Disease Diagnostics Market:

Segmentation 1: by Application

  • Laboratory Testing
  • Point of Care

Laboratory Testing to Dominate the India Emerging Infectious Disease Diagnostics Market (by Application)

Based on application, the laboratory testing segment dominated India emerging infectious disease diagnostics market in FY2024. Laboratory testing plays a crucial role in the diagnosis and management of infectious diseases. It involves the analysis of patient samples, such as blood, urine, sputum, or tissue, to detect the presence of infectious agents. Microbiological culture is a common technique that involves incubating patient samples on specific growth media to isolate and identify bacteria, fungi, or parasites, which can then be visualized through microscopy.

Segmentation 2: by Technology

  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Next-Generation Sequencing (NGS)
  • Immunodiagnostics
  • Other Technologies

Based on technology, India emerging infectious disease diagnostics market was dominated by the PCR segment in FY2024. Nowadays, PCR is usually used in several laboratories around the world, as it amplifies DNA further, allowing the analysis of even small amounts of nucleic acid. With growing technological advancements in molecular biology techniques, PCR has been utilized in several fields, including disease diagnosis, DNA profiling, precision medicine, and gene expression.

Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.

Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).

Segmentation 3: by Type of Infection

  • Bacterial
  • Viral
  • Fungal
  • Other Infections (Parasitic etc)

Bacterial and Viral Segments to Dominate the India Emerging Infectious Disease Diagnostics Market (by Type of Infection)

Based on the type of infection, bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.

Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.

Segmentation 4: by Disease Type

  • Respiratory Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Infections (STIs)
  • Neurological Infections
  • Post-Transplant Infections
  • Other Infections

Respiratory Infections to Dominate the India Emerging Infectious Disease Diagnostics Market (by Disease Type)

A vast majority of molecular diagnostic companies offer tests for various kinds of bacteria and viruses responsible for causing respiratory infections. Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as reverse transcriptase PCR (RT-PCR) and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus.

Segmentation 5: by End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Other End Users

Hospitals and Clinics and Diagnostic Laboratories to Dominate the India Emerging Infectious Disease Diagnostics Market (by End User)

Based on end users, the hospitals and clinics, and diagnostic laboratories segments accounted for the largest share of the India emerging infectious disease diagnostics market in FY2024. Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing. These laboratory facilities employ various methods, including molecular techniques such as PCR and sequencing, serological assays, and culture-based methods to identify and characterize infectious agents accurately.

Recent Developments in the India Emerging Infectious Disease Diagnostics Market

  • In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a pact on test kits for infectious diseases.
  • In February 2023, Biotech startup CrisprBits raised $250,000 in a pre-seed funding round to support the development and commercialization of its CRISPR-based tests.
  • In February 2023, the Food and Drug Administration (FDA) authorized the Xpert Mpox test by Cepheid (parent: DANAHER CORPORATION) for emergency use.
  • In August 2022, Bio-Rad Laboratories, Inc. acquired Curiosity Diagnostics to gain access to PCR ONE, a technology being developed by Curiosity Diagnostics, which can quickly detect a broad range of pathogens.
  • In June 2021, Hologic, Inc. completed the acquisition of Mobidiag to expand its capabilities in molecular diagnostics.
  • In January 2023, CrisprBits developed India's first CRISPR-based SARS-CoV-2 test with Omicron detection.
  • In March 2023, an India-based startup, Mylab Discovery Solutions Pvt. Ltd., entered into a joint venture with AstraGene LLC, the U.A.E.'s first molecular diagnostics manufacturing company to develop molecular diagnostics in the U.A.E. and Kuwait.
  • In November 2022, Bio-Rad Laboratories, Inc. and NuProbe entered into an exclusive licensing agreement for digital PCR applications.

How can India emerging infectious disease diagnostics market report add value to an organization?

Workflow/Innovation Strategy: India emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: In the India emerging infectious disease diagnostics market product launches, upgradations, and approvals accounted for the maximum number of key developments.

Competitive Strategy: The India emerging infectious disease diagnostics market is fragmented with several established as well as emerging players. Key players in the India emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Methodology

Key Considerations and Assumptions in India Emerging Infectious Disease Diagnostics Market Engineering and Validation

  • The base year considered for the calculation of India emerging infectious disease diagnostics market size is 2024. The historical year analysis has been done from FY2021 to FY2023, and the market size has been estimated for FY2024 and projected for the period 2025-2035.
  • The regional distribution of the India emerging infectious disease diagnostics market revenue has been estimated to be the same as the company's net revenue distribution. All the numbers have been adjusted off to two digits after decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the forecast period 2025-2035.
  • The market has been mapped based on different types of products available in the India emerging infectious disease diagnostics market for various applications. All key companies having a significant number of offerings for the India emerging infectious disease diagnostics market have been considered and profiled in the report.
  • The primary respondent's verification has been considered to finalize the estimated market for the India emerging infectious disease diagnostics market.
  • The latest annual reports of each market player have been taken into consideration for India emerging infectious disease diagnostics market revenue calculation.
  • Market strategies and developments of key players have been considered for the calculation of the sub-segment split.
  • The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website.

Primary Research

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding of the numbers of the various markets for market type
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), World Health Organization (WHO), and Indian Council of Medical Research (ICMR)
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their portfolio
  • Gold standard magazines, journals, whitepapers, press releases, and news articles
  • Databases

The key data points taken from the secondary sources include:

  • Segmentations, split-ups, and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis for India Emerging Infectious Disease Diagnostics:

Infectious disease diagnostics encompass a range of methods and techniques used to identify and detect infectious agents in individuals suspected of having an infection. These diagnostics play a vital role in timely diagnosis and accuracy, enabling appropriate treatment decisions and public health interventions.

There are two major approaches in the field; one is microbiological culture, which is a fundamental approach in which patient specimens are cultured on specialized growth media to isolate and identify specific pathogens. This technique allows for the determination of the causative organism and the assessment of its antimicrobial susceptibility. Molecular diagnostics, another important approach, utilizes techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) to detect the genetic material of the infectious agent. This enables highly sensitive and specific identification of pathogens, even at low concentrations.

Some of the prominent companies in India emerging infectious disease diagnostics market are:

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthcare AG
  • Thermo Fisher Scientific Inc.
  • DANAHER CORPORATION
  • Hologic, Inc.
  • Trivitron Healthcare
  • Genes2Me
  • CrisprBits
  • D-NOME Pvt Ltd
  • Co-Diagnostics, Inc.
  • DiaSorin S.p.A.
  • QIAGEN N.V.

Table of Contents

Executive Summary

Scope of Study

Research Methodology

1. India Emerging Infectious Disease Diagnostics Market Overview

  • 1.1 Market Outlook
    • 1.1.1 Market Overview
      • 1.1.1.1 Epidemiology of Infectious Diseases In India
        • 1.1.1.1.1 Respiratory Infection
          • 1.1.1.1.1.1 Influenza A and B
          • 1.1.1.1.1.1.1 Incidence
          • 1.1.1.1.1.1.2 Diagnosis rate
          • 1.1.1.1.1.1.3 Target Patient Pool
          • 1.1.1.1.1.2 RSV
          • 1.1.1.1.1.2.1 Incidence
          • 1.1.1.1.1.2.2 Diagnosis rate
          • 1.1.1.1.1.2.3 Target Patient Pool
          • 1.1.1.1.1.3 Mycoplasma Infections
          • 1.1.1.1.1.3.1 Incidence
          • 1.1.1.1.1.3.2 Diagnosis rate
          • 1.1.1.1.1.3.3 Target Patient Pool
          • 1.1.1.1.1.4 Pertussis
          • 1.1.1.1.1.4.1 Incidence
          • 1.1.1.1.1.4.2 Diagnosis rate
          • 1.1.1.1.1.4.3 Target Patient Pool
          • 1.1.1.1.1.5 Sexually Transmitted Infections (STIs)
          • 1.1.1.1.1.5.1 Incidence
          • 1.1.1.1.1.5.2 Diagnosis rate
          • 1.1.1.1.1.5.3 Target Patient Pool
          • 1.1.1.1.1.6 HIV/AIDS
          • 1.1.1.1.1.6.1 Incidence
          • 1.1.1.1.1.6.2 Diagnosis rate
          • 1.1.1.1.1.6.3 Target Patient Pool
          • 1.1.1.1.1.7 HPV Infection
          • 1.1.1.1.1.7.1 Incidence
          • 1.1.1.1.1.7.2 Diagnosis rate
          • 1.1.1.1.1.7.3 Target Patient Pool
          • 1.1.1.1.1.8 Herpes
          • 1.1.1.1.1.8.1 Incidence
          • 1.1.1.1.1.8.2 Diagnosis rate
          • 1.1.1.1.1.8.3 Target Patient Pool
          • 1.1.1.1.1.9 Gonorrhoea
          • 1.1.1.1.1.9.1 Incidence
          • 1.1.1.1.1.9.2 Diagnosis rate
          • 1.1.1.1.1.9.3 Target Patient Pool
          • 1.1.1.1.1.10 Syphilis
          • 1.1.1.1.1.10.1 Incidence
          • 1.1.1.1.1.10.2 Diagnosis rate
          • 1.1.1.1.1.10.3 Target Patient Pool
        • 1.1.1.1.2 Gastrointestinal Infections
          • 1.1.1.1.2.1 Colitis
          • 1.1.1.1.2.1.1 Incidence
          • 1.1.1.1.2.1.2 Diagnosis rate
          • 1.1.1.1.2.1.3 Target Patient Pool
          • 1.1.1.1.2.2 Peptic Ulcer
          • 1.1.1.1.2.2.1 Incidence
          • 1.1.1.1.2.2.2 Diagnosis rate
          • 1.1.1.1.2.2.3 Target Patient Pool
          • 1.1.1.1.2.3 Diarrhoea
          • 1.1.1.1.2.3.1 Incidence
          • 1.1.1.1.2.3.2 Diagnosis rate
          • 1.1.1.1.2.3.3 Target Patient Pool
        • 1.1.1.1.3 Neurological Infections
          • 1.1.1.1.3.1 Meningitis
          • 1.1.1.1.3.1.1 Incidence
          • 1.1.1.1.3.1.2 Diagnosis rate
          • 1.1.1.1.3.1.3 Target Patient Pool
          • 1.1.1.1.3.2 Encephalitis
          • 1.1.1.1.3.2.1 Incidence
          • 1.1.1.1.3.2.2 Diagnosis rate
          • 1.1.1.1.3.2.3 Target Patient Pool
        • 1.1.1.1.4 Post-Transplant Infections
          • 1.1.1.1.4.1 CMV Infection
          • 1.1.1.1.4.1.1 Incidence
          • 1.1.1.1.4.1.2 Diagnosis rate
          • 1.1.1.1.4.1.3 Target Patient Pool
          • 1.1.1.1.4.2 Sepsis
          • 1.1.1.1.4.2.1 Incidence
          • 1.1.1.1.4.2.2 Diagnosis rate
          • 1.1.1.1.4.2.3 Target Patient Pool
          • 1.1.1.1.4.3 Antimicrobial Resistance
          • 1.1.1.1.4.3.1 Microbe Resistance
          • 1.1.1.1.4.3.2 Key Causative Agent
          • 1.1.1.1.4.3.3 Preventive Measures to Limit AMR
          • 1.1.1.1.4.3.4 Challenges
    • 1.1.2 Most Preferred Platform for Infectious Disease Diagnosis
      • 1.1.2.1 Rapid Antigen Test (RAT)
      • 1.1.2.2 Polymerase Chain Reaction (PCR)
      • 1.1.2.3 Next Generation Sequencing (NGS)
    • 1.1.3 Timeline of Emerging Technologies for Infectious Disease Diagnostics
    • 1.1.4 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
    • 1.1.5 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
  • 1.2 Market Dynamics
    • 1.2.1 Market Opportunities and Trends
    • 1.2.2 Market Drivers
      • 1.2.2.1 Impact Analysis
    • 1.2.3 Market Restraints
      • 1.2.3.1 Impact Analysis

2. India Emerging Infectious Disease Diagnostics Market Analysis (by Application), $Million, 2023-2035

  • 2.1 Overview
  • 2.2 Laboratory Testing
  • 2.3 Point-of-Care Testing

3. India Emerging Infectious Disease Diagnostics Market Analysis (by Technology), $Million, 2023-2035

  • 3.1 Overview
  • 3.2 PCR
    • 3.2.1 Real Time PCR
    • 3.2.2 Digital PCR
  • 3.3 Immunodiagnostics
  • 3.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 3.5 Next Generation Sequencing (NGS)
  • 3.6 Other Technologies

4. India Emerging Infectious Disease Diagnostics Market Analysis (by Type of Infection), $Million, 2023-2035

  • 4.1 Overview
  • 4.2 Bacterial
  • 4.3 Viral
  • 4.4 Fungal
  • 4.5 Other Infections (Parasite)

5. India Emerging Infectious Disease Diagnostics Market Analysis (By Disease Type), $Million, 2023-2035

  • 5.1 Overview
  • 5.2 Respiratory Infection
  • 5.3 Gastrointestinal Infection
  • 5.4 Sexually Transmitted Infections (STIs)
  • 5.5 Neurological Infection
  • 5.6 Post-Transplant Infection
  • 5.7 Other Infection

6. India Emerging Infectious Disease Diagnostics Market Analysis (By End User), $Million, 2023-2035

  • 6.1 Overview
  • 6.2 Hospitals and Clinics
  • 6.3 Diagnostic Laboratories
  • 6.4 Other End User

7. India Emerging Infectious Disease Diagnostics Market - Competitive Benchmarking and Company Profiles

  • 7.1 Competitive Benchmarking
  • 7.2 Competitive Landscape
    • 7.2.1 Key Strategies and Developments by Company
      • 7.2.1.1 Funding Activities
      • 7.2.1.2 Mergers and Acquisitions
      • 7.2.1.3 Regulatory Approvals
      • 7.2.1.4 Partnerships, Collaborations and Business Expansions
    • 7.2.2 Key Developments Analysis
    • 7.2.3 Company Share Analysis
  • 7.3 Company Profiles
    • 7.3.1 Abbott Laboratories
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Product Portfolio
      • 7.3.1.3 Target Customers/End Users
      • 7.3.1.4 Analyst View
    • 7.3.2 Becton, Dickson and Company
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Product Portfolio
      • 7.3.2.3 Target Customers/End Users
      • 7.3.2.4 Analyst View
    • 7.3.3 bioMerieux S.A.
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Product Portfolio
      • 7.3.3.3 Target Customers/End Users
      • 7.3.3.4 Analyst View
    • 7.3.4 Bio-Rad Laboratories, Inc
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Product Portfolio
      • 7.3.4.3 Target Customers/End Users
      • 7.3.4.4 Analyst View
    • 7.3.5 Co-Diagnostics, Inc.
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Product Portfolio
      • 7.3.5.3 Target Customers/End Users
      • 7.3.5.4 Analyst View
    • 7.3.6 Danaher Corporation
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Product Portfolio
      • 7.3.6.3 Target Customers/End Users
      • 7.3.6.4 Analyst View
    • 7.3.7 DiaSorin S.p.A
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Product Portfolio
      • 7.3.7.3 Target Customers/End Users
      • 7.3.7.4 Analyst View
    • 7.3.8 F. Hoffmann-La Roche Ltd
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Product Portfolio
      • 7.3.8.3 Target Customers/End Users
      • 7.3.8.4 Analyst View
    • 7.3.9 Hologic, Inc
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Product Portfolio
      • 7.3.9.3 Target Customers/End Users
      • 7.3.9.4 Analyst View
    • 7.3.10 QIAGEN N.V.
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Product Portfolio
      • 7.3.10.3 Target Customers/End Users
      • 7.3.10.4 Analyst View
    • 7.3.11 Thermo Fisher Scientific, Inc.
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Product Portfolio
      • 7.3.11.3 Target Customers/End Users
      • 7.3.11.4 Analyst View
    • 7.3.12 Siemens Healthineers AG
      • 7.3.12.1 Company Overview
      • 7.3.12.2 Product Portfolio
      • 7.3.12.3 Target Customers/End Users
      • 7.3.12.4 Analyst View
  • 7.4 Emerging Companies Snapshot
    • 7.4.1 Trivitron Healthcare
    • 7.4.2 Genes2Me
    • 7.4.3 CrisprBits
    • 7.4.4 D-NOME Pvt Ltd.

8. Research Methodology

List of Figures

  • Figure: India Emerging Infectious Disease Diagnostics Market, Market Dynamics Impact Analysis
  • Figure: India Emerging Infectious Disease Diagnostics Market Coverage
  • Figure: India Emerging Infectious Disease Diagnostics Market Key Trends, Impact Analysis, 2022-2025
  • Figure: India Emerging Infectious Disease Diagnostics Market, Patent Analysis, January 2022-March 2025
  • Figure: India Emerging Infectious Disease Diagnostics Market, Competitive Landscape, January 2022-March 2025

List of Tables

  • Table: India Emerging Infectious Disease Diagnostics Market, Comparative Analysis
  • Table: India Emerging Infectious Disease Diagnostics Market, Regulatory Scenario
  • Table: India Emerging Infectious Disease Diagnostics Market, Impact Analysis
  • Table: India Emerging Infectious Disease Diagnostics Market (by Application), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by Technology), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by Disease Type), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2023-2035